1. Introduction {#sec1}
===============

*Plasmodium vivax* is responsible for the majority of malaria cases in Southeast Asia and remains the second most common cause of malaria in the world after *Plasmodium falciparum* ([@bib42]; [@bib45]; [@bib46]). Malaria incidences in Thailand are reducing, with the exception of the regions of the country that border Myanmar and Cambodia, where the disease remains highly prevalent ([@bib44]). These regions are particularly affected by the prevalence of multi-drug resistant strains of *P. falciparum*, including parasites that are resistant to artemisinin. The selection and spread of drug resistance in such border regions is linked to the migration of worker populations from neighboring countries, the epidemiology of parasite transmission in such areas, and the patterns of anti-malarial drug usage amongst the local populations ([@bib24]; [@bib14]). Although most of the focus regarding drug resistant malaria parasites falls on *P. falciparum*, *P. vivax* is the most prevalent malaria parasite species in these regions. Despite this, there have been relatively few surveys of drug resistance in this species, and little is known regarding the prevalence of genetic markers of drug resistance in this region.

As the selection and spread of *P. falciparum* mutants resistant to multiple drugs occurs frequently in this region, it might be expected that such selection would also occur in *P. vivax*, as it is presumably exposed to similar selection mechanisms. However, there are relatively few reports documenting the prevalence of drug resistant *P. vivax* parasites in the border regions of Thailand.

Chloroquine resistance (CQR) has been reported for *P. vivax* worldwide including in Thailand. Potential molecular markers include mutations in the multidrug resistance 1 (*mdr1*) and putative transporter protein CG 10 (*crt-o*) genes, orthologous to *Pfmdr1* and *Pfcrt* in *P. falciparum*, respectively ([@bib7]; [@bib39]). Point mutations in *Pvdhfr* and *Pvdhps* are linked to decreased sensitivity to Sulphadoxine-pyrimethamine (SP) ([@bib17]), and previous studies from Thailand have shown high prevalences of mutants in the border regions ([@bib42]). Artemisinin resistance in *P. falciparum* is linked to mutations in the *Kelch 13* (*Pfk13*) gene, and high prevalences of mutant alleles have been observed in Southeast Asia ([@bib2]; [@bib27]). There are limited studies on the prevalence of mutations in the *P. vivax* orthologue of this gene (*Pvk12*), although three studies that looked for polymorphisms at this locus from samples collected in Southeast Asia between 2008 and 2013 suggest that there is limited polymorphism present ([@bib33]; [@bib10]; [@bib43]).

In order to survey the prevalence of mutations associated with drug resistance in *P. vivax* in the border regions of Thailand, and to investigate how these prevalences have changed through time, we analysed mutations in *Pvdhfr, Pvdhps, Pvmdr1, Pvcrt-o* and *Pvk12* from *P. vivax* parasites isolated from four regions of Thailand (three along the Thai-Myanmar, and one along the Thai-Cambodia border) in 2008--2009 and 2014--2015.

2. Materials and methods {#sec2}
========================

2.1. Collection sites and parasite isolates {#sec2.1}
-------------------------------------------

Three hundred and forty-five *P. vivax* field isolates were collected during two periods: February 2008 to February 2009 (n = 220) and July 2014 to July 2015 (n = 125) from patients attending the malaria clinics in four different geographical locations in Thailand along the Thai-Myanmar (2008--2009; 14, 84 and 37, 2014--2015; 32, 53 and 20 isolates from Mae Hong Son, Tak and Prachuap Khiri Khan Provinces, respectively) and Thai-Cambodian (2008--2009; 85, 2014--2015; 20 isolates from Chanthaburi Province) borders. The prevalence of malaria in Thailand is, on average, 3 cases per 1000 population. The predominant malaria species in this region are *P. vivax* (54%) and *P. falciparum* (38%). CQ plus primaquine (PQ) remains the standard treatment of *P. vivax* infection in Thailand whereas artesunate--mefloquine is the first-line artemisinin combination therapy (ACT) for *P. falciparum* ([@bib45]). Blood samples were collected before anti-malarial treatment from patients by finger-prick, and applied to glass slides for microscopy. The presence of *P. vivax* was confirmed by analysis of thick and thin blood smears, and by species-specific PCR to exclude mixed infections. Additionally, blood (200--300 μL) was collected onto filter paper (Whatman No. 3), and genomic DNA extracted using a QIAamp mini DNA kit (Qiagen, Germany), according to the manufacturer\'s instruction and stored at −20 °C until use.

2.2. Polymerase chain reaction (PCR) amplification for *Pvdhfr, Pvdhps, Pvmdr1, Pvcrt-o* and *Pvk12* {#sec2.2}
----------------------------------------------------------------------------------------------------

To amplify *Pvdhfr, Pvdhps, Pvmdr1, Pvcrt-o* and *Pvk12*, both nested PCR and single PCR amplification methods were used following established protocols with some modifications ([@bib6]; [@bib24], [@bib25]; [@bib11]; [@bib33]). Oligonucleotide primers and cycling conditions are listed in [Table 1](#tbl1){ref-type="table"}. All amplification reactions were carried out in a total volume of 25 μL containing dH~2~O, 0.2 μM of each primer (10 pM), 1.75 mM of MgCl~2~ (25 mM), 0.3 U of Taq polymerase (5 U/μL), 200 μM of dNTP mixture (10 mM each), and 1x of (10x)PCR buffer following the manufacturer\'s instructions (New England Biolabs^®^ Inc., Ipswich, MA). 2.0 μL of template genomic DNA was used in primary amplification reactions, and 1.0 μL of primary reaction products was used in the second round of amplification in the case of nested PCRs. The amplified PCR products were resolved on 1.0% agarose gel, and the sizes of the PCR products were determined using a 1-Kb DNA ladder (New England Biolabs^®^ Inc., Ipswich, MA). PCR products were stored at −20 °C until analysis.Table 1The primers and cycling conditions used to amplify *Pvdhfr*, *Pvdhps*, *Pvmdr1*, *Pvcrt-o* and *Pvk12* of *P. vivax* isolates.Table 1GenesSequences (5' → 3′)PCR cycling conditionsProduct size (bp)Reference*Pvdhfr* (1st)F: CACCGCACCAGTTGATTCCT94 °C 5 min/\[94 °C 30 s, 58 °C 30 s, 68 °C 1 min\] × 20 cycles, 68 °C 5 min979[@bib11]R: CCTCGGCGTTGTTCTTCT*Pvdhfr* (2nd)F: CCCCACCACATAACGAAG94 °C 5 min/\[94 °C 30 s, 58 °C 30 s, 68 °C 45 s\] × 40 cycles, 68 °C 5 min755R: CCCCACCTTGCTGTAAACC*Pvdhps* (1st)F: GATGGCGGTTTATTTGTCG94 °C 5 min/\[94 °C 30 s, 59 °C 30 s, 68 °C 1 min\] × 20 cycles, 68 °C 5 min1009R: GCTGATCTTTGTCTTGACG*Pvdhps* (2nd)F: GCTGTGGAGAGGATGTTC94 °C 5 min/\[94 °C 30 s, 59 °C 30 s, 68 °C 45 s\] × 40 cycles, 68 °C 5 min731R: CCGCTCATCAGTCTGCAC*Pvmdr1* (1st)F: ACGACATGATCCAAACGACA94 °C 5 min/\[94 °C 30 s, 60 °C 30 s, 68 °C 3 min\] × 20 cycles, 68 °C 5 min2784[@bib6]R: CTTATATACGCCGTCCTGCAC*Pvmdr1* (2nd)F: GGATAGTCATGCCCCAGGATTG94 °C 5 min/\[94 °C 30 s, 62 °C 1 min, 68 °C 45 s\] × 40 cycles, 68 °C 5 min604[@bib24]R: CATCAACTTCCCGGCGTAGC*Pvcrt-o*F: AAGAGCCGTCTAGCCATCC94 °C 5 min/\[94 °C 30 s, 62 °C 1 min, 68 °C 1.30 min\] × 40 cycles, 68 °C 5 min1186[@bib25]R: AGTTTCCCTCTACACCCG*Pvk12* (1st)F: ATCCAACAGCATTTCCAACT94 °C 15 min/\[94 °C 30 s, 58 °C 1 min,682 °C 2.10 min\] × 20 cycles, 68 °C 10 min2108[@bib33]R: CAATTAAAACGGAATGTCCA*Pvk12* (2nd)F: ACCACGTGACGAGGGATAAG94 °C 15 min/\[94 °C 30 s, 62 °C 1 min, 68 °C 1.30 min\] × 20 cycles, 68 °C 10 min1015R: AAAACGGAATGTCCAAATCG

2.3. Sequence analysis of *Pvdhfr, Pvdhps, Pvmdr1, Pvcrt-o* and *Pvk12* {#sec2.3}
-----------------------------------------------------------------------

The PCR products of *Pvdhfr, Pvdhps, Pvmdr1, Pvcrt-o* and *Pvk12* were sequenced using an ABI 3730 DNA Analyzer (Applied Biosystems). Nucleotide and amino acid sequences of *Pvdhfr, Pvdhps, Pvmdr1, Pvcrt-o* and *Pvk12* were aligned and compared with the following reference sequences originated from the *Sal1* strain of *P. vivax*; *Pvdhfr* (accession no. XM001615032), *Pvdhps* (accession no. XM001617159), *Pvmdr1* (accession no. XM001613678), *Pvcrt-o* (accession no. XM001613407) and *Pvk1*2 (accession no. XM001614165) using ATGC version 5.0.2 (Genetyx corporation, Japan) and MEGA version 4 ([@bib41]).

The *Pvdhfr, Pvdhps, Pvmdr1, Pvcrt-o* and *Pvk12* gene sequences of all *P. vivax* isolates determined in this study were deposited in the GeneBank database under accession numbers; Pvdhfr: MG867734 to MG867971, Pvdhps: MG867972 to MG868211, Pvmdr1: MG868212 to MG868424, Pvcrt-o: MG868425 to MG868616, and Pvk12: MG868617 to MG868911, respectively.

2.4. Statistical analysis {#sec2.4}
-------------------------

The SNPs data of drug resistant genes were analysed using MS Excel and SPSS (Version 24.0. IBM Corp., Armonk, NY, USA) in individual, between years and among different areas. Pearson\'s Chi-square test was used to determine statistical significance (*P*-value \< 0.001). When the data did not meet the assumptions of the Chi-square test (80% of the cells having expected values of five or more, and no one cell having an expected value less than one), Fisher\'s exact test was applied ([@bib28]).

2.5. Ethics statement {#sec2.5}
---------------------

Permission for this study was obtained from the ethical review committee for research in human subjects, Ministry of Public Health, Thailand (Reference no. 101/2550 and 34/2557).

3. Results {#sec3}
==========

3.1. Prevalence of *Pvdhfr* and *Pvdhps* mutations {#sec3.1}
--------------------------------------------------

*P. vivax* populations from four regions and two time points (2008 and 2014) were sampled. Three of these regions are located on the Thai-Myanmar border and one at the Thai-Cambodia border.

For isolates collected in 2008, mutations in *Pvdhfr* at codons 57, 58, 61 and 117 were detected in 77.4%, 100%, 77.4% and 100%, respectively of isolates from the Thai-Myanmar border. At the Thai-Cambodian border, all isolates carried mutations at codons 58 and 117 only ([Table 2](#tbl2){ref-type="table"}). A similar pattern was observed in 2014, with all isolates from the Thai-Cambodia border carrying the double mutant haplotype F~57~**[R]{.ul}**~58~T~61~**[N]{.ul}**~117~, whereas mutations in *Pvdhfr* at codons 57, 58, 61 and 117 were present in 70.1%, 100%, 70.1% and 100%, respectively, of isolates collected from the Thai-Myanmar border. Comparing *Pvdhfr* haplotype prevalence for all samples between 2008 and 2014, reveals a general increase in the prevalence of the **[I]{.ul}**~57~**[R]{.ul}**~58~**[M]{.ul}**~61~H~99~**[T]{.ul}**~117~I~173~ quadruple mutant from 43% (2008) to 53.2% (2014) ([Table 3](#tbl3){ref-type="table"}).Table 2Prevalence of mutations conferring resistance to CQ and SP in *P. vivax* isolates and comparison of mutant codons in *P. vivax* isolates collected between 2008 and 2014 classified by border region.Table 2GenotypeMutation at codonNumber of isolates (%)*P*-valueNumber of isolates (%)*P*-valueTotalYear 2008Year 2014Thai-MyanmarThai-CambodianThai-MyanmarThai-Cambodian*Pvdhfrn* = *84n* = *60n* = *77n* = *17n* = *238*5765 (77.4)0\<0.00154 (70.1)0\<0.001119 (50)5884 (100)60 (100)NR77 (100)17 (100)NR238 (100)6165 (77.4)0\<0.00154 (70.1)0\<0.001119 (50)9900NR00NR011784 (100)60 (100)NR77 (100)17 (100)NR238 (100)17300NR00NR0*Pvdhpsn* = *86n* = *66n* = *80n* = *8n* = *240*38213 (15.1)00.00124 (30)00.10137 (15.4)38383 (96.5)31 (47)\<0.00137 (46.3)8 (100)0.006159 (66.3)51200NR4 (5)01.0004 (1.7)55372 (83.7)0\<0.00175 (93.8)0\<0.001147 (61.3)58000NR00NR058500NR00NR0*Pvdmdr1n* = *82n* = *44n* = *73n* = *14n* = *213*95882 (100)44 (100)NR73 (100)14 (100)NR213 (100)97626 (31.7)42 (95.5)\<0.0018 (11)9 (64.3)\<0.00185 (39.9)99700NR00NR0107651 (62.2)40 (90.9)0.00129 (39.7)14 (100)\<0.001134 (62.9)*Pvcrt-on* = *60n* = *60n* = *78n* = *14n* = *212*4700NR00NR07600NR00NR0[^2][^3]Table 3Prevalence of single nucleotide polymorphism haplotypes in *Pvdhfr*, *Pvdhps*, *Pvmdr1* and *Pvcrt-o* of *P. vivax* isolates.Table 3Gene locusHaplotypeCodonNumber of isolates (%)*P*-valueYear 2008Year 2014Total*Pvdhfr*57/58/61/99/117/173*n* = *144n* = *94n* = *238*Wild-typeFSTHSI000NRDouble mutantF**[R]{.ul}**T**−[N]{.ul}**I79 (54.9)40 (42.5)119 (50)0.084Quadruple mutant (a)**[LRM]{.ul}**H**[T]{.ul}**I3 (2.1)4 (4.3)7 (2.9)0.439Quadruple mutant (b)**[IRM]{.ul}**H**[T]{.ul}**I62 (43)50 (53.2)112 (47.1)0.145*Pvdhps*382/383/512/553/580/585*n* = *152n* = *88n* = *240*Wild-typeSAKARV37 (24.3)037 (15.5)\<0.001Single mutantS**[G]{.ul}**KARV43 (28.3)13 (14.8)56 (23.3)0.012Double mutantS**[G]{.ul}**K**[G]{.ul}**RV59 (38.8)49 (55.7)108 (45)0.007Triple mutant (a)**[AG]{.ul}**K**[G]{.ul}**RV13 (8.6)22 (25)35 (14.6)0.001Triple mutant (b)S**[GMG]{.ul}**RV01 (1.1)1 (0.4)0.367Triple mutant (c)S**[GEG]{.ul}**RV01 (1.1)1 (0.4)0.367Quadruple mutant**[AGMG]{.ul}**RV02 (2.3)2 (0.8)0.133*Pvmdr1*958/976/997/1076*n* = *126n* = *87n* = *213*Wild-typeTYKF000NRSingle mutant**[M]{.ul}**YKF29 (23)43 (49.4)72 (33.8)\<0.001Double mutant (a)**[MF]{.ul}**KF6 (4.8)1 (1.2)7 (3.3)0.144Double mutant (b)**[M]{.ul}**YK**[L]{.ul}**29 (23)27 (31)56 (26.3)0.156Triple mutant**[MF]{.ul}**K**[L]{.ul}**62 (49.2)16 (18.4)78 (36.6)\<0.001*Pvcrt-o*47/76*n* = *120n* = *92n* = *212*Wild-typeLK120 (100)92 (100)212 (100)NR[^4][^5][^6]

Analysis of *Pvdhfr* haplotype prevalence at each sampling site revealed that the quadruple mutant (**[I]{.ul}**~57~**[R]{.ul}**~58~**[M]{.ul}**~61~**[T]{.ul}**~117~) predominates along the Thai-Myanmar border both in 2008 and 2014, whereas it is absent from the Thai-Cambodia border at both time points ([Fig. 1](#fig1){ref-type="fig"}). However, in all three provinces along the Thai-Myanmar border there was a decrease in the prevalence of the quadruple mutant (**[I]{.ul}**~57~**[R]{.ul}**~58~**[M]{.ul}**~61~**[T]{.ul}**~117~) between 2008 and 2014, and this was associated with the appearance and expansion of the quadruple mutant (**[L]{.ul}**~57~**[R]{.ul}**~58~**[M]{.ul}**~61~**[T]{.ul}**~117~) in Mae Hong Son and Prachuap Khiri Khan, as well as a slight increase in prevalence of the F~57~**[R]{.ul}**~58~T~61~**N**~117~ double mutant in all three provinces ([Fig. 1](#fig1){ref-type="fig"}).

In 2008, the majority of isolates from the Thai-Myanmar border carried mutations in *Pvdhps* at codons 383 (96.5%) and codon 553 (83.7%). The picture at the Thai-Cambodia border was markedly different, with 53% of isolates showing the wild-type allele, with the remainder (47%) carrying a single mutation at position 383. By 2014, the prevalence of the 383 mutation at the Thai-Myanmar border had dropped to 46.3%, whereas it had increased to 100% at the Thai-Cambodian border, although the sample size for this population is low (n = 8). The prevalence of the mutation at codon 553 was unchanged between the two sampling times at both borders ([Table 2](#tbl2){ref-type="table"}).

Considering isolated from both border regions, there was a general increase in double and triple *Pvdhps* mutants between 2008 and 2014, and a reduction in the prevalence of the single mutant and wild-type parasites, the latter reduction being statistical significance ([Table 3](#tbl3){ref-type="table"}).

The prevalences of *Pvdhps* mutant parasites in the four sampling regions in 2008 and 2014 are shown in [Fig. 2](#fig2){ref-type="fig"}. The double mutant S~382~**[G]{.ul}**~383~K~512~**[G]{.ul}**~553~ dominates in the north part of the Thai-Myanmar border, whereas the triple mutant **[A]{.ul}**~382~**[G]{.ul}**~383~K~512~**[G]{.ul}**~553~ is more prevalent in the south, and these patterns are generally conserved between sampling times, with a slight increase in the triple mutant observed in both regions. The situation is dramatically different at the Thai-Cambodia border, where the only the wild type (47%) and single mutant S~382~**[G]{.ul}**~383~K~512~A~553~ (53%) were present in 2008, and only the single mutant in 2014.

3.2. Prevalence of *Pvmdr1* and *Pvcrt-o* mutations {#sec3.2}
---------------------------------------------------

Mutations at codons *Pvmdr1* 958, 976 and 1076 were observed in all sampling areas at both time points. In 2008, the 958 mutation was found in 100% of all isolates from both border regions, and by 2014, the mutation was at fixation at both borders. Mutations at both 976 and 1076 were more prevalent along the Thai-Cambodia border than at the Thai-Myanmar border with statistical significance, and these were more prevalent in 2008 than in 2014 in both regions ([Table 2](#tbl2){ref-type="table"}). There were no mutations observed in *Pvcrt-o* in either region at either time point.

Combining samples from all regions, there was a decrease from 49.2% to 18.4% in the prevalence of the triple mutant **[M]{.ul}**~958~**[F]{.ul}**~976~**[L]{.ul}**~1076~ between 2008 and 2014, and an increase in the prevalence of the single mutant **[M]{.ul}**~958~Y~976~F~1076~ from 23% to 49.4% with statistical significance. ([Table 3](#tbl3){ref-type="table"}).

The prevalences of mutations in *Pvmdr1* for all sampling areas and both times are shown in [Fig. 3](#fig3){ref-type="fig"}. The single mutant **[M]{.ul}**~958~Y~976~F~1076~ increased in prevalence between 2008 and 2014 the Thai-Myanmar border in Mae Hong Son and Prachuap Khiri Khan, but remained stable in Tak. At Chanthaburi on the Thai-Cambodia border, where the single mutant **[M]{.ul}**~958~Y~976~F~1076~ is absent, there was an increase in the prevalence of the double **[M]{.ul}**~958~Y~976~**[L]{.ul}**~1076~ mutant. There was a decrease in the prevalence of the triple mutant **[M]{.ul}**~958~**[F]{.ul}**~976~**[L]{.ul}**~1076~ in all regions between 2008 and 2014.Fig. 1Prevalence of alleles of the *Pvdhfr* gene in *P. vivax* samples collected at four malaria endemic districts of Thailand. The small and big circle represent year 2008 and 2014, respectively. (The two numbers followed each province name represent the numbers of isolates sequenced in 2008, 2014) (bold with underline letters indicate mutant amino acids).Fig. 1Fig. 2Prevalence of alleles of the *Pvdhps* gene in *P. vivax* samples collected at four malaria endemic districts of Thailand. The small and big circle represent year 2008 and 2014, respectively. (The two numbers followed each province name represent the numbers of isolates sequenced in 2008, 2014) (bold with underline letters indicate mutant amino acids).Fig. 2Fig. 3Prevalence of alleles of the *Pvmdr1* gene in *P. vivax* samples collected at four malaria endemic districts of Thailand. The small and big circle represent year 2008 and 2014, respectively. (The two numbers followed each province name represent the numbers of isolates sequenced in 2008, 2014) (bold with underline letters indicate mutant amino acids).Fig. 3

3.3. Variation and distribution of different tandem repeat sequences in the *Pvdhfr* gene {#sec3.3}
-----------------------------------------------------------------------------------------

Two different tandem repeat variations were found in *Pvdhfr* sequences analysed here. Type 1 was identical to the *Sal I* reference strain (accession no. [X98123](ncbi-n:X98123){#intref0010}) while type 2 included a deletion of six amino acids at positions 98--103 (THGGDN) ([Fig. 4](#fig4){ref-type="fig"}A). Type 2 was observed in all samples isolated from the Thai-Cambodian border in both sampling years, whereas Type 1 was most common in isolates from the Thai-Myanmar border (77.4%, 70.1% in year 2008 and 2014, respectively) ([Fig. 4](#fig4){ref-type="fig"}B). In addition, all isolates with type 2 tandem repeat deletion carried the S117N mutation.Fig. 4Distribution and prevalence of tandem repeat variants *Pvdhfr* collected from Thai-Myanmar and Thai-Cambodian borders. (A) Sequences alignment of Type 1 (wild type, accession no. [X98123](ncbi-n:X98123){#intref0020}) and Type 2 amino-acid repeat regions. Dashes (−) represent tandem repeat deletions between amino acid position 82 and 109. Bold underlined letters indicate the tandem repeat. (B) Prevalences of two tandem repeat types obtained from *P. vivax* isolates from the Thai-Myanmar border (black) and Thai-Cambodian border (blue). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 4

3.4. Prevalence polymorphisms in *Pvk12* {#sec3.4}
----------------------------------------

In total, three non-synonymous and three synonymous mutations were observed in the *Pvk12* gene in all isolates assayed in 2008 ([Table 4](#tbl4){ref-type="table"}). Non-synonymous mutations M548I and K596R were observed in samples collected from Chanthaburi Province, and P641L was observed in Tak. Synonymous mutations were identified at amino acid residue F437 in Prachuap Khiri Khan Province, and at amino acid residues N675, C682 in isolates collected from Tak Province. No mutations were observed in 2014.Table 4Mutations in the *P. vivax K12* propeller gene, Thailand, 2008.Table 4MutationAmino acid change and locationGenetic changeStudy site (no. isolates)NonsynonymousM548IATG→ATAChanthaburi (1/184)K596RAAG→AGGChanthaburi (1/184)P641LCCG→CTGTak (1/184)SynonymousF437TTC→TTTPrachuap Khiri Khan (1/184)N675AAT→AACTak (1/184)C682TGT→TGCTak (1/184)

4. Discussion {#sec4}
=============

The greater Mekong region has witnessed the *de novo* selection and spread of mutations conferring drug resistance to *P. falciparum* malaria parasites ([@bib30]). In Thailand, *P. vivax*, either in mono-infections or co-infections with *P. falciparum* accounts for approximately half of the malaria cases observed ([@bib8]; [@bib21]). It is reasonable to suppose, therefore, that the drug pressures driving the selection of *P. falciparum* drug resistance in this region also apply to *P. vivax*, and yet data pertaining to the prevalence of mutations linked to resistance in this latter species is rather sparse. It is also likely that *P. vivax* parasites are exposed to drugs that are not routinely prescribed for the treatment of this species, but rather for *P. falciparum*, as a result of co-infection or through the inoculation of *P. vivax* sporozoites into individuals undergoing drug treatment for an earlier *P. falciparum* episode. It is necessary therefore, to assay the *P. vivax* population for mutations in genes linked to resistance to a wide range of antimalarial drugs not limited to those used to treat *P. vivax* specifically.

Here we present data regarding the prevalence of mutations in *Pvdhfr*, *Pvdhps*, *Pvmdr1*, *Pvcrt-o* and *Pvk12* in *P. vivax* parasites isolated from four border regions of Thailand in 2008 and 2014.

4.1. Prevalence of mutations in genes linked to resistance to antifolate drugs {#sec4.1}
------------------------------------------------------------------------------

The emergence and spread of strains of *P. vivax* with reduced susceptibility to antifolate drugs has contributed to an increase in morbidity associated with this parasite in Southeast Asia ([@bib14]). In Thailand, SP was the first line treatment for *P. falciparum* since 1972 and was then used in combination with mefloquine (MQ) from 1996 before being phased out by the end of 2001 ([@bib35]). However, it is still widely used for self-medication of fever. Thus there has been, and perhaps continues to be, a lengthy selection pressure for SP-resistant strains of *P. vivax* ([@bib16]; [@bib36]).

Resistance to antifolates in *P. vivax* appears to be linked to mutations in *Pvdhfr* and *Pvdhps* gene polymorphisms ([@bib13]), orthologous to the mutations in *Pfdhfr* and *Pfdhps* known to confer resistance to these drugs in *P. falciparum* ([@bib14]).

Here, we analysed the prevalence of alleles of *Pvdhfr* (n = 238 isolates) and *Pvdhp*s (n = 240 isolates) from the Thai-Myanmar and Thai-Cambodian borders in 2008 and 2014. The most prevalent of alleles observed in samples collected from the Thai-Myanmar border at both time points was the quadruple *Pvdhfr* mutant (**[L/I]{.ul}**~57~**[R]{.ul}**~58~**[M]{.ul}**~61~**[T]{.ul}**~117~) with the double *Pvdhps* mutant (S~382~**[G]{.ul}**~383~K~512~**[G]{.ul}**~553~). However, the triple *Pvdhps* mutant allele (**[A]{.ul}**~382~**[G]{.ul}**~383~K~512~**[G]{.ul}**~553~) was highly prevalent in Prachuap Khiri Khan Province in both years (43% in 2008 and 56% in 2014). In contrast, isolates from the Thai-Cambodian border carried the *Pvdhfr* double mutant (F~57~**[R]{.ul}**~58~T~61~**[T]{.ul}**~117~) exclusively at both time points, along with the either the wild-type or single mutant *Pvdhp*s allele (53% of wild-type and 47% of single mutant (S~382~**[G]{.ul}**~383~K~512~A~553~) allele) in 2008, and exclusively with the single *Pvdhps* mutant in 2014 ([Supplementary Table 1](#appsec1){ref-type="sec"}).

Many previous studies from Thailand and surrounding regions have demonstrated an increase in the prevalence of *Pvdhfr* and *Pvdhps* alleles containing multiple mutations through time. For example, the majority parasites isolated from *P. vivax* infected patients admitted to the Tropical Medicine Hospital, Thailand between 1995 and 1998, carried the triple *Pvdhfr* mutant (**[L]{.ul}**~57~**[R]{.ul}**~58~T~61~**N**~117~) allele and the double mutant *Pvdhps* (**G**~383~**G**~553~) ([@bib15]). Isolates collected from Tak province (Thai-Myanmar border) in 2005 commonly carried the quadruple *Pvdhfr* mutant (**[L/I]{.ul}**~57~**[R]{.ul}**~58~**[M]{.ul}**~61~**[T]{.ul}**~117~) (81.3%) and the double *Pvdhps* mutant allele (62.5%) ([@bib35]), and this pattern was observed along the Thai-Myanmar border. In contrast, and consistent with our findings, the double mutant *Pvdhfr* combined with the single mutant *Pvdhp*s allele was the most common parasite genotype in isolates from the Thai-Cambodian border at that time ([@bib36]). More recently, [@bib42] reported a high prevalence of quadruple mutant *Pvdhfr* (**[L/I]{.ul}**~57~**[R]{.ul}**~58~**[M]{.ul}**~61~**[T]{.ul}**~117~) and wild-type *Pvdhps* carrying parasites in isolates from the Thai-Myanmar border (Mae Hong Son and Ranong Provinces) in 2011, while the double mutant *Pvdhfr* (F~57~**[R]{.ul}**~58~T~61~**[T]{.ul}**~117~) and wild-type *Pvdhps* dominated at the Thai-Cambodian border (Trat and Sisaket Provinces) ([@bib42]).

It appears that in *P. vivax*, as in *P. falciparum*, mutations in *dhfr* are acquired in a step-wise manner, and their accumulation corresponds to the degree of resistance against pyrimethamine conferred to the parasite ([@bib23]; [@bib38]). Combined with previous surveys of the prevalence of *Pvdhfr* and *Pvhdps* mutations from this region, our results are consistent with the hypothesis that selection for parasites with increased resistance to SP has occurred, at least until 2014 at the Thai-Myanmar border, and to a lesser extent, at the Thai-Cambodia border. We found a complete absence of wild-type *Pvdhfr* alleles (F~57~S~58~T~61~S~117~) from either border at both sampling time points. Similarly, there were no wild-type *Pvdhps* (S~382~A~383~K~512~A~553~) alleles from either border region in 2014, although 53% and 2.3% of isolates collected from the Thai-Cambodian border and the Thai-Myanmar border respectively carried the wild-type allele in 2008. This paucity of wild-type alleles has previously been observed in this region in recent times ([@bib42]).

It has previously been suggested that the tandem repeat polymorphism in the *Pvdhfr* gene can be used as a marker for *P. vivax* SP resistance ([@bib23]). We observed the monomorphic tandem repeat region (type 2) in samples from the Thai-Cambodian border in both years of sampling. This allele includes a deletion of six nucleotides at position 98--103 (THGGDN). All isolates of this type also carried a mutation at residue 117 (S117N), which is consistent with a previous study from Thailand ([@bib16]). In contrast, most isolates from the Thai-Myanmar border carried the type 1 tandem repeat region, along with a S117T mutation ([@bib35]; [@bib23]). This suggests that the type 1 tandem repeat is associated with increased resistance to SP, as previously noted ([@bib9]), however the exact nature of the relationship between this polymorphism and parasite sensitivity to SP remains unclear.

Mutations in *Pvdhps* alleles at positions S382A, A383G, K512M/E, A553G and V585A have been associated with reduced sensitivity to sulfadoxine ([@bib14]). Alleles of *Pvdhps* with mutations at these positions are more frequent in areas with high SP use than in regions of low SP use. Moreover, the double mutant allele (**G**~383~**G**~553~) displays reduced binding affinity between the *PvDHPS* domain and sulfadoxine *in vitro* and *in vivo* compared to the wild-type allele ([@bib17]; [@bib6]). However, it has also been reported that other mutations in the gene, including S382A, A383G and A553G, do not influence enzyme catalytic activity ([@bib34]). We did not detect mutations at V585 in any isolates in this study. Mutations at this locus, orthologous to the V613 of *P. falciparum*, have been proposed to be involved in resistance to sulfadoxine and other sulfa drugs ([@bib3]; [@bib36]). Similarly, no mutations were observed at codon 173 of the *Pvdhfr* gene, where a mutation (I173L) has been shown to be involved in clinical antifolate resistance ([@bib16]).

The presence and high prevalence of mutations in *Pvdhfr* and *Pvdhps* in the isolates collected during this study, suggest that SP resistant *P. vivax* parasites from this region have undergone selection, despite the fact that SP has never been recommended for use as a treatment against this parasite species. The selection of SP resistance in *P. vivax* may be caused by the widespread use of SP against falciparum malaria in these regions, and perhaps through the introduction of resistant parasites from the neighboring countries of Cambodia and Myanmar. Certainly, the high prevalence of mutations associated with resistance to SP in these populations precludes the use of antifolates as treatments for vivax malaria in Thailand.

4.2. Prevalence of mutations in *Pvmdr1 and Pvcrt-o* genes {#sec4.2}
----------------------------------------------------------

CQ has been the first-line treatment for *P. vivax* malaria in Thailand since 1946. The first appearance of *P. falciparum* resistance to CQ occurred in the 1950s, but it was not until 1989 that the first report of resistance in *P. vivax* appeared, from parasites isolated in Papua New Guinea. There have been, until very recently, no reports of *P. vivax* resistance to CQ in Thailand ([@bib4]), and it remains an effective treatment for *P. vivax* malaria ([@bib14]). However, a recent study described high grade CQ resistance in infecting a pregnant woman from the Thai-Myanmar border ([@bib37]). Two genes, both encoding transporter proteins, have been implicated with CQR in *P. vivax; Pvmdr1* and *Pvcrt-o* ([@bib25]).

We assayed the prevalence of mutations in *Pvmdr1* and *Pvcrt-o* in 213 and 212 *P. vivax* sequences from the border regions of Thailand, respectively. The most prevalent *Pvmdr1* alleles in samples collected from the Thai-Myanmar border in 2008 were the single mutant (**[M]{.ul}**~958~Y~976~K~997~F~1076~) (35.4%) and the double mutant (b) (**[M]{.ul}**~958~Y~976~K~997~**[L]{.ul}**~1076~) (32.9%). By 2014, the prevalence of the single mutant in this region had increased to 58.9%. At the Thai-Cambodian border, the triple mutant *Pvmdr1* (**[M]{.ul}**~958~**[F]{.ul}**~976~K~997~**[L]{.ul}**~1076~) dominated in both sampling years (86.4% in 2008 and 64.3% in 2014). No *Pvmdr1* wild-type alleles were observed ([Supplementary Table 1](#appsec1){ref-type="sec"}).

We observed a high prevalence of the *Pvmdr1* Y976F mutation in isolates from the Thai-Cambodian border in both sampling years (95.5% in 2008 and 64.3% in 2014) whereas this mutation was rarer at the Thai-Myanmar border. This result is consistent with previous studies on *P. vivax* isolates from Thailand ([@bib7]; [@bib18]; [@bib37]), Myanmar ([@bib18]) and Cambodia ([@bib22]). The Y976F mutation was observed, however, in all double (a) and triple mutant alleles from all areas at both sampling periods.

The *Pvmdr1* Y976F mutation has been associated with a low-level decrease in *vitro* susceptibility to CQ ([@bib39]; [@bib24]). However, other *in vitro* studies have suggested that this mutation reduces susceptibility to MQ, while increasing susceptibility to CQ ([@bib40]). MQ replaced CQ as the first-line treatment for *P. falciparum* to Thailand in 1983, and was combined with artesunate as a component of ACT in 1990 ([@bib20]). Other studies have shown that the prevalence of mutations in *Pvmdr1* is higher in areas with current or past intense use of MQ such as in French Guiana and Cambodia, than it is in regions where it has never been used ([@bib20]). Furthermore, in Thailand and Cambodia, an increasing prevalence of parasites currying mutations in *Pfmdr1* has been linked to the decreasing efficacy of ACT ([@bib12]).

We observed no mutations in *Pvcrt-o* in any of the samples tested during this study, a result congruent with previous studies in Thailand ([@bib24]; [@bib37]; [@bib31]). It has been suggested that there may be no correlation between CQ resistance in *P. vivax* and mutations in this gene ([@bib26]; [@bib5]). In addition, a lysine (K) insertion in the first exon (amino acid position 10) has been found to be linked to a significant decrease in CQ drug sensitivity assays ([@bib39]; [@bib24]). This polymorphism was not observed in any of the samples from this study. Given the widespread occurrence of mutations in *Pvmdr1*, and their known association with *P. vivax* resistance to CQ conserved here, alternative drugs should possibly be considered for the first line treatment of *P. vivax* in Thailand, especially in light of recent reports documenting treatment failure with this drug.

4.3. Prevalence of mutations in *Pvk12* gene {#sec4.3}
--------------------------------------------

Mutations in the *P. falciparum* Kelch 13 gene (*Pfk13*) are known to be associated with reduced sensitivity to artemisinin and its derivatives in *P. falciparum* ([@bib1]; [@bib2]). Many countries in the Greater Mekong Sub-region of Southeast Asia and China have reported numerous mutations in the *Pfk13* gene and many of these appear to be associated with artemisinin resistance ([@bib1]; [@bib2]; [@bib29]; [@bib27]). There appears to be selection acting on these mutations in the Greater Mekong Region, as their prevalence has increased throughout the years artemisinin has been used. The situation in *P. vivax* is, however, much less clear, with genetic diversity observed in the orthologous *Pvk12* gene ([@bib33]; [@bib10]; [@bib32]; [@bib43]).

We found six point-mutations in *Pvk12* from 154 *P. vivax* isolates collected from Tak, Prachuap Khiri Khan and Chanthaburi Provinces in 2008. Three non-synonymous mutations (1.9%) at M548I, K596R and P641L and three synonymous mutations (1.9%) at F437, C675 and C682 were found. All mutations were present at very low prevalence in 2008, and only the wild-type allele was observed in 111 samples from 2014. This suggests that there is no selection for mutations in this gene in the border regions of Thailand, in contrast to the apparent strong selection for mutations in the orthologous *P. falciparum* K13 gene ([@bib19]), and this is consistent with previous studies from the region.

There are multiple possible explanations for why we do not observe any apparent selection for *Pvk12* mutations in Thailand, despite the high prevalence of *Pfk13* mutants in the *P. falciparum* population. Firstly, it is possible that selection for reduced sensitivity to artemisinin has not occurred in *P. vivax*, perhaps due to reduced exposure to this drug compared to *P. falciparum*. Given the selection observed on *P. vivax dhfr* and *dhps*, presumably caused by exposure to SP, however, this seems unlikely. Secondly, it is possible that the mechanism of resistance against artemisinin does not involve the *Pvk12* gene, in much the same way that *Pvcrt-o* does not appear to be linked to CQ resistance in *P. vivax*. Lastly, there may be biological and pharmacological explanations, perhaps involving the gametocidal properties of artemisinin, which prevent *P. vivax* acquiring resistance despite strong selection pressure.

In conclusion, these results show that mutations associated with resistance SP are widespread and prevalent along the border regions of Thailand, despite the fact that SP is not officially used in the treatment of vivax malaria. The prevalence of these mutations differences between the Thai-Myanmar and Thai-Cambodia borders, with fewer mutations associated with the later area. This situation is reversed in the case of mutations in *Pvmdr1*, with parasites at the Thai-Cambodia harboring a greater number of mutations in the gene on average than those at the Thai-Myanmar border. These differences may be attributed, at least partly, to differences in anti-malarial drug usage in Myanmar and Cambodia.

Possible explanations for how drugs used exclusively against *P. falciparum* could drive the evolution of resistance in *P. vivax* include; i) treatment of co-infections in which *P. vivax* is cryptic, ii) treatment of *P. falciparum*, followed by infection with *P. vivax* before the presence of the drug in the blood has been eliminated, iii) self-treatment of *P. vivax* infection with drugs that should be used against *P. falciparum* (self-diagnosis and treatment).

Finally, we did not find any evidence for the selection of mutations in *Pvk12*, the *P. vivax* orthologue of the artemisinin-resistance linked *Pfk13* gene in *P. falciparum*.

Appendix A. Supplementary data {#appsec1}
==============================

The following is the supplementary data related to this article:Multimedia component 1Multimedia component 1
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